Prognostic model for patient survival in primary anorectal mucosal melanoma: stage at presentation determines relevance of histopathologic features.


Journal

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
ISSN: 1530-0285
Titre abrégé: Mod Pathol
Pays: United States
ID NLM: 8806605

Informations de publication

Date de publication:
03 2020
Historique:
received: 02 05 2019
accepted: 07 07 2019
revised: 06 07 2019
pubmed: 7 8 2019
medline: 26 1 2021
entrez: 7 8 2019
Statut: ppublish

Résumé

Pathological staging of primary anorectal mucosal melanoma is often performed according to the American Joint Commission on Cancer (AJCC) guidelines for cutaneous melanoma, as an anorectal melanoma-specific staging system does not exist. However, it remains unknown whether prognostic factors derived for cutaneous melanoma also stratify risk in anorectal melanoma. We retrospectively determined correlations between clinicopathological parameters and disease-specific survival in 160 patients. Patients were grouped by clinical stage at presentation (localized disease, regional or distant metastases). Cox proportional hazards regression models determined associations with disease-specific survival. We also summarized the somatic mutations identified in a subset of tumors analyzed for hotspot mutations in cancer-associated gene panels. Most of the patients were white (82%) and female (61%). The median age was 62 years. With a median follow-up of 1.63 years, median disease-specific survival was 1.75 years, and 121 patients (76%) died of anorectal melanoma. Patients presenting with regional (34%) or distant metastases (24%) had significantly shorter disease-specific survival compared to those with disease localized to the anorectum (42%). Of the 71 anorectal melanoma tumors analyzed for hotspot genetic alterations, somatic mutations involving the KIT gene (24%) were most common followed by NRAS (19%). Increasing primary tumor thickness, lymphovascular invasion, and absence of regression also correlated with shorter disease-specific survival. Primary tumor parameters correlated with shorter disease-specific survival in patients presenting with localized disease (tumor thickness) or regional metastases (tumor thickness, absence of regression, and lymphovascular invasion), but not in patients presenting with distant metastases. Grouping of patients according to a schema based on modifications of the 8th edition AJCC cutaneous melanoma staging system stratified survival in anorectal melanoma. Our findings support stage-specific associations between primary tumor parameters and disease-specific survival in anorectal melanoma. Moreover, the AJCC cutaneous melanoma staging system and minor modifications of it predicted survival among anorectal melanoma patients.

Identifiants

pubmed: 31383963
doi: 10.1038/s41379-019-0340-7
pii: S0893-3952(22)00918-8
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

496-513

Références

Callahan A, Anderson WF, Patel S, Barnholtz-Sloan JS, Bordeaux JS, Tucker MA, et al. Epidemiology of anorectal melanoma in the United States: 1992 to 2011. Dermatol Surg. 2016;42:94–9.
doi: 10.1097/DSS.0000000000000579 pubmed: 26655698 pmcid: 26655698
Chen H, Cai Y, Liu Y, He J, Hu Y, Xiao Q, et al. Incidence, surgical treatment, and prognosis of anorectal melanoma from 1973 to 2011: a population-based SEER analysis. Medicine. 2016;95:1–8.
doi: 10.1097/MD.0000000000004558
Taylor JP, Stem M, Yu D, Chen SY, Fang SH, Gearhart SL, et al. Treatment strategies and survival trends for anorectal melanoma: is it time for a change? World J Surg. 2019;43:1809–19.
doi: 10.1007/s00268-019-04960-w pubmed: 30830243 pmcid: 30830243
Ragnarsson-Olding BK, Nilsson PJ, Olding LB, Nilsson BR. Primary ano-rectal malignant melanomas within a population-based national patient series in Sweden during 40 years. Acta Oncol. 2009;48:125–31.
doi: 10.1080/02841860802120861 pubmed: 18607861 pmcid: 18607861
Kelly P, Zagars GK, Cormier JN, Ross MI, Guadagnolo BA. Sphincter-sparing local excision and hypofractionated radiation therapy for anorectal melanoma: a 20-year experience. Cancer. 2011;117:4747–55.
doi: 10.1002/cncr.26088 pubmed: 21446049 pmcid: 21446049
Brady MS, Kavolius JP, Quan SH. Anorectal melanoma. A 64-year experience at Memorial Sloan-Kettering Cancer Center. Dis Colon Rectum. 1995;38:146–51.
doi: 10.1007/BF02052442
Ross M, Pezzi C, Pezzi T, Meurer D, Hickey R, Balch C. Patterns of failure in anorectal melanoma. A guide to surgical therapy. Arch Surg. 1990;125:313–6.
doi: 10.1001/archsurg.1990.01410150035007
Ranjith S, Muralee M, Sajeed A, Arun PM, Cherian K, Nair CK, et al. Anorectal melanoma: experience from a tertiary cancer care centre in South India. Ann R Coll Surg Engl. 2017;100:1–5.
Hicks CW, Pappou EP, Magruder JT, Gazer B, Fang S, Wick EC, et al. Clinicopathologic presentation and natural history of anorectal melanoma: a case series of 18 patients. JAMA Surg. 2014;149:608–11.
doi: 10.1001/jamasurg.2013.4643 pubmed: 24848283 pmcid: 24848283
Heppt MV, Roesch A, Weide B, Gutzmer R, Meier F, Loquai C, et al. Prognostic factors and treatment outcomes in 444 patients with mucosal melanoma. Eur J Cancer. 2017;81:36–44.
doi: 10.1016/j.ejca.2017.05.014 pubmed: 28600969 pmcid: 28600969
Cronin KA, Lake AJ, Scott S, Sherman RL, Noone AM, Howlader N, et al. Annual report to the nation on the status of cancer, part I: National cancer statistics. Cancer. 2018;124:2785–800.
doi: 10.1002/cncr.31551 pubmed: 29786848 pmcid: 29786848
Aulmann S, Sinn HP, Penzel R, Gilks CB, Schott S, Hassel JC, et al. Comparison of molecular abnormalities in vulvar and vaginal melanomas. Mod Pathol. 2014;27:1386–93.
doi: 10.1038/modpathol.2013.211 pubmed: 24603591 pmcid: 24603591
Santi R, Simi L, Fucci R, Paglierani M, Pepi M, Pinzani P, et al. KIT genetic alterations in anorectal melanomas. J Clin Pathol. 2015;68:130–4.
doi: 10.1136/jclinpath-2014-202572 pubmed: 25398993 pmcid: 25398993
Yang HM, Hsiao SJ, Schaeffer DF, Lai C, Remotti HE, Horst D, et al. Identification of recurrent mutational events in anorectal melanoma. Mod Pathol. 2017;30:286–96.
doi: 10.1038/modpathol.2016.179 pubmed: 27739435 pmcid: 27739435
Faure M, Rochigneux P, Olive D, Taix S, Brenot-Rossi I, Gilabert M. Hyperprogressive disease in anorectal melanoma treated by PD-1 inhibitors. Front Immunol. 2018;9:797.
doi: 10.3389/fimmu.2018.00797 pubmed: 29725330 pmcid: 29725330
Shoushtari AN, Munhoz RR, Kuk D, Ott PA, Johnson DB, Tsai KK, et al. The efficacy of anti-PD-1 agents in acral and mucosal melanoma. Cancer. 2016;122:3354–62.
doi: 10.1002/cncr.30259 pubmed: 27533633 pmcid: 27533633
Dodds TJ, Wilmott JS, Jackett LA, Lo SN, Long GV, Thompson JF, et al. Primary anorectal melanoma: clinical, immunohistology and DNA analysis of 43 cases. Pathology. 2019;51:39–45.
doi: 10.1016/j.pathol.2018.09.060 pubmed: 30497801 pmcid: 30497801
Ballantyne AJ. Malignant melanoma of the skin of the head and neck. Anal 405 cases Am J Surg. 1970;120:425–31.
doi: 10.1016/S0002-9610(70)80001-0
Chang AE, Karnell LH, Menck HR. The National Cancer Data Base report on cutaneous and noncutaneous melanoma: a summary of 84,836 cases from the past decade. The American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer. 1998;83:1664–78.
doi: 10.1002/(SICI)1097-0142(19981015)83:8<1664::AID-CNCR23>3.0.CO;2-G
Pessaux P, Pocard M, Elias D, Duvillard P, Avril MF, Zimmerman P, et al. Surgical management of primary anorectal melanoma. Br J Surg. 2004;91:1183–7.
doi: 10.1002/bjs.4592
Ishizone S, Koide N, Karasawa F, Akita N, Muranaka F, Uhara H, et al. Surgical treatment for anorectal malignant melanoma: report of five cases and review of 79 Japanese cases. Int J Colorectal Dis. 2008;23:1257–62.
doi: 10.1007/s00384-008-0529-6 pubmed: 18633625 pmcid: 18633625
Weyandt GH, Eggert AO, Houf M, Raulf F, Brocker EB, Becker JC. Anorectal melanoma: surgical management guidelines according to tumour thickness. Br J Cancer. 2003;89:2019–22.
doi: 10.1038/sj.bjc.6601409 pubmed: 14647131 pmcid: 14647131
Che X, Zhao DB, Wu YK, Wang CF, Cai JQ, Shao YF, et al. Anorectal malignant melanomas: retrospective experience with surgical management. World J Gastroenterol. 2011;17:534–9.
doi: 10.3748/wjg.v17.i4.534 pubmed: 3027022 pmcid: 3027022
Yen CI, Chen HH, Chiang SF, Yeh CY, Chen JS, Hsieh PS, et al. Anorectal melanoma: review of 22 consecutive cases. Hepatogastroenterology. 2013;60:89–93.
pubmed: 22829553 pmcid: 22829553
Gershenwald JE, Scolyer RA, Hess KR, et al. Melanoma of the skin. In: Amin MB, et al., editors. AJCC cancer staging manual 8 edn. Switzerland: Springer; 2017. pp. 563–85.
Balch CM, Gershenwald JE, Atkins MB, Buzaid AC, Cascinelli N, Cochran AJ. Melanoma of the skin. In: Edge SB, Byrd DR, Compton CC, et al., editors. AJCC cancer staging manual, 7th edn. New York: Springer International Publishing; 2010. pp. 325–46.
Ballo MT, Gershenwald JE, Zagars GK, Lee JE, Mansfield PF, Strom EA, et al. Sphincter-sparing local excision and adjuvant radiation for anal-rectal melanoma. J Clin Oncol. 2002;20:4555–8.
doi: 10.1200/JCO.2002.03.002 pubmed: 12454112 pmcid: 12454112
Breslow A. Prognosis in cutaneous melanoma: tumor thickness as a guide to treatment. Pathol Annu. 1980;15:1–22.
pubmed: 7443304 pmcid: 7443304
Clark WH Jr., Elder DE, Dt Guerry, Braitman LE, Trock BJ, Schultz D, et al. Model predicting survival in stage I melanoma based on tumor progression. J Natl Cancer Inst. 1989;81:1893–904.
doi: 10.1093/jnci/81.24.1893 pubmed: 2593166 pmcid: 2593166
Thompson JF, Soong SJ, Balch CM, Gershenwald JE, Ding S, Coit DG, et al. Prognostic significance of mitotic rate in localized primary cutaneous melanoma: an analysis of patients in the multi-institutional American Joint Committee on Cancer melanoma staging database. J Clin Oncol. 2011;29:2199–205.
doi: 10.1200/JCO.2010.31.5812 pubmed: 21519009 pmcid: 21519009
Tetzlaff MT, Curry JL, Ivan D, Wang WL, Torres-Cabala CA, Bassett RL, et al. Immunodetection of phosphohistone H3 as a surrogate of mitotic figure count and clinical outcome in cutaneous melanoma. Mod Pathol. 2013;26:1153–60.
doi: 10.1038/modpathol.2013.59 pubmed: 23558574 pmcid: 23558574
Balch CM, Wilkerson JA, Murad TM, Soong SJ, Ingalls AL, Maddox WA. The prognostic significance of ulceration of cutaneous melanoma. Cancer. 1980;45:3012–7.
doi: 10.1002/1097-0142(19800615)45:12<3012::AID-CNCR2820451223>3.0.CO;2-O pubmed: 7388745 pmcid: 7388745
Aung PP, Nagarajan P, Prieto VG. Regression in primary cutaneous melanoma: etiopathogenesis and clinical significance. Lab Invest. 2017;97:657–68.
doi: 10.1038/labinvest.2017.8
Kashani-Sabet M, Sagebiel RW, Ferreira CM, Nosrati M, Miller JR 3rd. Vascular involvement in the prognosis of primary cutaneous melanoma. Arch Dermatol. 2001;137:1169–73.
doi: 10.1001/archderm.137.9.1169 pubmed: 11559212 pmcid: 11559212
Baer SC, Schultz D, Synnestvedt M, Elder DE. Desmoplasia and neurotropism. Progn Var patients stage I melanoma Cancer. 1995;76:2242–7.
Kimsey TF, Cohen T, Patel A, Busam KJ, Brady MS. Microscopic satellitosis in patients with primary cutaneous melanoma: implications for nodal basin staging. Ann Surg Oncol. 2009;16:1176–83.
doi: 10.1245/s10434-009-0350-7 pubmed: 19224283 pmcid: 19224283
Schatton T, Scolyer RA, Thompson JF, Mihm MC Jr. Tumor-infiltrating lymphocytes and their significance in melanoma prognosis. Methods Mol Biol. 2014;1102:287–324.
doi: 10.1007/978-1-62703-727-3_16 pubmed: 24258985 pmcid: 24258985
Damsky WE, Bosenberg M. Melanocytic nevi and melanoma: unraveling a complex relationship. Oncogene. 2017;36:5771–92.
doi: 10.1038/onc.2017.189 pubmed: 28604751 pmcid: 28604751
Gershenwald JE, Scolyer RA, Hess KR, Sondak VK, Long GV, Ross MI, et al. Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017;67:472–92.
doi: 10.3322/caac.21409 pubmed: 29028110 pmcid: 29028110
Nagarajan P, Curry JL, Ning J, Piao J, Torres-Cabala CA, Aung PP, et al. Tumor thickness and mitotic rate robustly predict melanoma-specific survival in patients with primary vulvar melanoma: a retrospective review of 100 cases. Clin Cancer Res. 2017;23:2093–104.
doi: 10.1158/1078-0432.CCR-16-2126 pubmed: 27864417 pmcid: 27864417
Stockman DL, Curry JL, Torres-Cabala CA, Watson IR, Siroy AE, Bassett RL, et al. Use of clinical next-generation sequencing to identify melanomas harboring SMARCB1 mutations. J Cutan Pathol. 2015;42:308–17.
doi: 10.1111/cup.12481 pubmed: 25754356 pmcid: 25754356
Upton J. Fisher’s Exact Test. J R Stat Soc Ser A. 1991;192:395–402.
Schemper M, Smith TL. A note on quantifying follow-up in studies of failure time. Control Clin Trials. 1996;17:343–6.
doi: 10.1016/0197-2456(96)00075-X pubmed: 8889347 pmcid: 8889347
Kaplan E, Meier P. Nonparametric estimator from incomplete observations. J Am Stat Assoc. 1958;53:457–81.
doi: 10.1080/01621459.1958.10501452
Harrington DP, Fleming TR. A class of rank test procedures for censored survival data. Biometrika. 1982;69:553–66.
doi: 10.1093/biomet/69.3.553
Cox D. Regression models and life tables. J R Stat Soc: Ser B. 1972;34:187–220.
Thibault C, Sagar P, Nivatvongs S, Ilstrup DM, Wolff BG. Anorectal melanoma–an incurable disease? Dis Colon Rectum. 1997;40:661–8.
doi: 10.1007/BF02140894 pubmed: 9194459 pmcid: 9194459
Bello DM, Smyth E, Perez D, Khan S, Temple LK, Ariyan CE, et al. Anal versus rectal melanoma: does site of origin predict outcome? Dis Colon Rectum. 2013;56:150–7.
doi: 10.1097/DCR.0b013e31827901dd pubmed: 23303142 pmcid: 23303142
Roumen RM. Anorectal melanoma in The Netherlands: a report of 63 patients. Eur J Surg Oncol. 1996;22:598–601.
doi: 10.1016/S0748-7983(96)92346-X pubmed: 9005147 pmcid: 9005147
Wanebo HJ, Woodruff JM, Farr GH, Quan SH. Anorectal melanoma. Cancer. 1981;47:1891–900.
doi: 10.1002/1097-0142(19810401)47:7<1891::AID-CNCR2820470730>3.0.CO;2-K pubmed: 6164474 pmcid: 6164474
Row D, Weiser MR. Anorectal melanoma. Clin Colon Rectal Surg. 2009;22:120–6.
doi: 10.1055/s-0029-1223844 pubmed: 20436837 pmcid: 20436837
Yeh JJ, Shia J, Hwu WJ, Busam KJ, Paty PB, Guillem JG, et al. The role of abdominoperineal resection as surgical therapy for anorectal melanoma. Ann Surg. 2006;244:1012–7.
doi: 10.1097/01.sla.0000225114.56565.f9 pubmed: 17122627 pmcid: 17122627
Ribero S, Gualano MR, Osella-Abate S, Scaioli G, Bert F, Sanlorenzo M, et al. Association of histologic regression in primary melanoma with sentinel lymph node status: a systematic review and meta-analysis. JAMA Dermatol. 2015;151:1301–7.
doi: 10.1001/jamadermatol.2015.2235 pubmed: 26332402 pmcid: 26332402
Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Ding S, Byrd DR, et al. Multivariate analysis of prognostic factors among 2,313 patients with stage III melanoma: comparison of nodal micrometastases versus macrometastases. J Clin Oncol. 2010;28:2452–9.
doi: 10.1200/JCO.2009.27.1627 pubmed: 20368546 pmcid: 20368546
Cheung MC, Perez EA, Molina MA, Jin X, Gutierrez JC, Franceschi D, et al. Defining the role of surgery for primary gastrointestinal tract melanoma. J Gastrointest Surg. 2008;12:731–8.
doi: 10.1007/s11605-007-0417-3 pubmed: 18058185 pmcid: 18058185
Falch C, Stojadinovic A, Hann-von-Weyhern C, Protic M, Nissan A, Faries MB, et al. Anorectal malignant melanoma: extensive 45-year review and proposal for a novel staging classification. J Am Coll Surg. 2013;217:324–35.
doi: 10.1016/j.jamcollsurg.2013.02.031 pubmed: 23697834 pmcid: 23697834
Nilsson PJ, Ragnarsson-Olding BK. Importance of clear resection margins in anorectal malignant melanoma. Br J Surg. 2010;97:98–103.
doi: 10.1002/bjs.6784
Podnos YD, Tsai NC, Smith D, Ellenhorn JD. Factors affecting survival in patients with anal melanoma. Am Surg. 2006;72:917–20.
pubmed: 17058735 pmcid: 17058735
Ramakrishnan AS, Mahajan V, Kannan R. Optimizing local control in anorectal melanoma. Indian J Cancer. 2008;45:13–9.
doi: 10.4103/0019-509X.40641 pubmed: 18453735 pmcid: 18453735
Zhou HT, Zhou ZX, Zhang HZ, Bi JJ, Zhao P. Wide local excision could be considered as the initial treatment of primary anorectal malignant melanoma. Chin Med J (Engl). 2010;123:585–8.
Ren M, Lu Y, Lv J, Shen X, Kong J, Dai B, et al. Prognostic factors in primary anorectal melanoma: a Clinicopathologic study of 60 cases in China. Hum Pathol. 2018;79:77–85.

Auteurs

Priyadharsini Nagarajan (P)

Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. pnagarajan@mdanderson.org.

Jin Piao (J)

Department of Clinical Preventive Medicine, University of Southern California, Los Angeles, CA, USA.
Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Jing Ning (J)

Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Laura E Noordenbos (LE)

Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Department of Surgical Oncology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.

Jonathan L Curry (JL)

Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Department of Dermatology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Carlos A Torres-Cabala (CA)

Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Department of Dermatology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

A Hafeez Diwan (AH)

Department of Pathology and Immunology, Baylor College of Medicine, Houston, TX, USA.

Doina Ivan (D)

Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Department of Dermatology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Phyu P Aung (PP)

Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Merrick I Ross (MI)

Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Richard E Royal (RE)

Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Jennifer A Wargo (JA)

Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Wei-Lien Wang (WL)

Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Rashmi Samdani (R)

Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Alexander J Lazar (AJ)

Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Department of Translational and Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Asif Rashid (A)

Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Michael A Davies (MA)

Department of Translational and Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Department of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Victor G Prieto (VG)

Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Department of Dermatology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Department of Translational and Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Jeffrey E Gershenwald (JE)

Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Michael T Tetzlaff (MT)

Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. mtetzlaff@mdanderson.org.
Department of Translational and Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. mtetzlaff@mdanderson.org.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH